Free Webex Call
The Catheter Related Bloodstream Infection Market was valued at USD 1.62 Billion in 2024, and is expected to reach USD 2.25 Billion by 2030, rising at a CAGR of 5.62%. The global Catheter Related Bloodstream Infection market is primarily driven by the increasing prevalence of hospital-acquired infections, particularly those associated with central venous catheters. Catheter related bloodstream infections are among the most frequent and serious complications of central venous catheter use, leading to significant morbidity, mortality, and healthcare costs. Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The rising incidence of bloodstream infections, especially in high-risk groups like immunocompromised patients undergoing treatments such as chemotherapy, further fuels market growth. The growing concern over antibiotic resistance, which complicates the treatment of catheter related bloodstream infections, has led to a rising demand for advanced diagnostic tools and infection prevention strategies. These combined factors are contributing to the expansion of the global Catheter Related Bloodstream Infection market.
Key Market Drivers
Increasing Prevalence of Hospital-Acquired Infections
Hospital-acquired infections (HAIs) are one of the most significant health concerns in medical settings globally. Catheter-related bloodstream infections (CRBSIs) are one of the leading types of HAIs, and their rising prevalence plays a substantial role in driving the growth of the global Catheter Related Bloodstream Infection market. These infections occur when pathogens enter the bloodstream through central venous catheters, a common medical device used for administering medications, fluids, and nutrients to critically ill patients. The growing number of patients requiring invasive procedures such as surgeries, dialysis, and long-term intravenous treatments leads to an increase in catheter usage, thus elevating the risk of CRBSIs.This, in turn, results in an increased demand for effective infection prevention and diagnostic solutions. According to WHO, On average, approximately 1 in 10 patients experiences healthcare-associated infections (HAIs); however, the incidence is notably higher in low- and middle-income countries, as well as among high-risk patients, such as those in intensive care units. According to a 2023 study by Balasubramanian et al., around 136 million cases of healthcare-associated antibiotic-resistant infections occur globally each year. In Europe, the impact of the six most common HAIs was found to be twice as significant as the combined burden of 32 other infectious diseases, in terms of disability and premature mortality. Additionally, it was estimated that 63.5% of infections caused by antibiotic-resistant bacteria are associated with healthcare settings.
Key Market Challenges
High Cost of Advanced Infection Prevention Technologies
One of the significant challenges in the global Catheter Related Bloodstream Infection market is the high cost of advanced infection prevention technologies. While innovative solutions such as antimicrobial-coated catheters, rapid diagnostic tools, and biofilm-resistant materials have proven effective in reducing infection rates, these technologies often come with a premium price.This cost barrier can be a challenge, especially in low-resource healthcare settings or emerging markets where budget constraints are a significant concern. Hospitals and healthcare providers may be hesitant to adopt these advanced solutions if they face financial limitations, despite the long-term benefits in terms of improved patient outcomes and reduced healthcare costs. The cost of training healthcare staff to effectively use these advanced technologies and maintain infection control protocols further compounds the financial burden on healthcare systems, making it difficult for some institutions to fully embrace these innovations.
Key Market Trends
Technological Advancements in Catheter Materials
Innovations in catheter design and material science are also contributing to the growth of the catheter-related bloodstream infection market. One significant development has been the introduction of antimicrobial-coated catheters, which are designed to reduce the risk of infection by inhibiting the growth of bacteria and other pathogens on the surface of the catheter.These catheters have been shown to significantly decrease the incidence of catheter-related bloodstream infections, especially in high-risk patient populations. In January 2025, Autonomix Medical, Inc. announced that it has achieved "design lock" for its Application Specific Integrated Circuits (ASIC) microchip. This milestone follows the successful completion of in vivo preclinical testing and extensive bench testing, marking continued progress toward the Company's U.S. pivotal trial.
The development of biofilm-resistant materials, which prevent the formation of bacterial biofilms on catheter surfaces, is further enhancing the safety and efficacy of catheters. As these technologies continue to advance, the demand for these more sophisticated catheter products is likely to grow, driving market expansion.
Key Market Players
- Teva Pharmaceutical Industries Ltd.
- SteriMax Inc.
- Sanofi S.A.
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- GSK plc
- Fresenius SE & Co. KGaA
- Eli Lilly and Company
- Aurobindo Pharma Limited
Report Scope:
In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Catheter Related Bloodstream Infection Market, By Treatment Type:
- Anti-microbial Agents
- Antibiotic Lock Therapy
Catheter Related Bloodstream Infection Market, By Source of Infection:
- Coagulase-negative Staphylococcus
- S. Aureus
- Enteric Gram-negative Bacilli
- Yeasts
- Enterococci & Streptococci
- Pseudomonas
- Others
Catheter Related Bloodstream Infection Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Catheter Related Bloodstream Infection Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Catheter Related Bloodstream Infection Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Global Catheter Related Bloodstream Infection Market Outlook
6. North America Catheter Related Bloodstream Infection Market Outlook
7. Europe Catheter Related Bloodstream Infection Market Outlook
8. Asia-Pacific Catheter Related Bloodstream Infection Market Outlook
9. South America Catheter Related Bloodstream Infection Market Outlook
10. Middle East and Africa Catheter Related Bloodstream Infection Market Outlook
11. Market Dynamics
12. Market Trends & Developments
13. Porter’s Five Forces Analysis
14. Competitive Landscape
Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- SteriMax Inc.
- Sanofi S.A.
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- GSK plc
- Fresenius SE & Co. KGaA
- Eli Lilly and Company
- Aurobindo Pharma Limited
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 182 |
Published | February 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 1.62 Billion |
Forecasted Market Value ( USD | $ 2.25 Billion |
Compound Annual Growth Rate | 5.6% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |